There is an increasing array of clinical, biochemical and molecular markers available to evaluate health and disease status. The groups expertise in the area is reflected by invitations for them to write review papers and book chapters.
Sometimes several biomarker tests are available to evaluate health or disease status, which can vary in their relationship to the outcome of interest, as well as their ease of use, time and cost. There is often one test that is regarded as being the most robust, i.e. the gold standard. Our team usually compares various biomarkers tests, before applying them to clinical studies.
To improve the prediction of future health outcomes and to monitor responses to treatments novel clinical, biochemical and molecular markers are often evaluated in relationship to existent or future health status.